Literature DB >> 2285615

ACE inhibitors in renovascular hypertension.

S C Textor1.   

Abstract

ACE inhibition has provided many insights into the etiology and treatment of renovascular hypertension. Not only have studies using these agents profoundly expanded our understanding of the mechanisms governing preservation of renal perfusion pressures and function beyond arterial lesions, they have provided tools for more precise diagnosis and therapy in clinical practice. ACE inhibitors must be considered the agents of choice for the treatment of renovascular hypertension and provide an effective and safe medical alternative for many patients developing atherosclerotic renovascular lesions with an otherwise unacceptable risk for revascularization procedures. With the advent of widespread clinical use of these agents, however, come many new questions regarding the long-term fate of the kidney beyond vascular lesions and the need for preservation of renal function.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2285615     DOI: 10.1007/bf01857637

Source DB:  PubMed          Journal:  Cardiovasc Drugs Ther        ISSN: 0920-3206            Impact factor:   3.727


  41 in total

1.  Effects of continuous converting enzyme blockade on renovascular hypertension in the rat.

Authors:  R H Freeman; J O Davis; B E Watkins; G A Stephens; J M DeForrest
Journal:  Am J Physiol       Date:  1979-01

2.  Inhibition of angiotensin-converting enzyme for diagnosis of renal-artery stenosis.

Authors:  R Re; R Novelline; M T Escourrou; C Athanasoulis; J Burton; E Haber
Journal:  N Engl J Med       Date:  1978-03-16       Impact factor: 91.245

3.  Renal damage induced in the clipped kidney of one-clip, two-kidney hypertensive rats during normalization of blood pressure by converting enzyme inhibition.

Authors:  J B Michel; J C Dussaule; L Choudat; D Nochy; P Corvol; J Ménard
Journal:  Kidney Int Suppl       Date:  1987-05       Impact factor: 10.545

4.  Clinical course of atherosclerotic renovascular disease.

Authors:  J Wollenweber; S G Sheps; G D Davis
Journal:  Am J Cardiol       Date:  1968-01       Impact factor: 2.778

5.  Effects of graded renal artery constriction on blood pressure, renal artery pressure, and plasma renin activity in Goldblatt hypertension.

Authors:  W R Murphy; T G Coleman; T L Smith; K A Stanek
Journal:  Hypertension       Date:  1984 Jan-Feb       Impact factor: 10.190

6.  Angiotensin II effects upon the glomerular microcirculation and ultrafiltration coefficient of the rat.

Authors:  R C Blantz; K S Konnen; B J Tucker
Journal:  J Clin Invest       Date:  1976-02       Impact factor: 14.808

Review 7.  Medical therapy for renovascular hypertension: a review.

Authors:  N K Hollenberg
Journal:  Am J Hypertens       Date:  1988-10       Impact factor: 2.689

8.  The natural history of atherosclerotic and fibrous renal artery disease.

Authors:  M J Schreiber; M A Pohl; A C Novick
Journal:  Urol Clin North Am       Date:  1984-08       Impact factor: 2.241

9.  Critical perfusion pressure for renal function in patients with bilateral atherosclerotic renal vascular disease.

Authors:  S C Textor; A C Novick; R C Tarazi; V Klimas; D G Vidt; M Pohl
Journal:  Ann Intern Med       Date:  1985-03       Impact factor: 25.391

10.  STUDIES ON EXPERIMENTAL HYPERTENSION : I. THE PRODUCTION OF PERSISTENT ELEVATION OF SYSTOLIC BLOOD PRESSURE BY MEANS OF RENAL ISCHEMIA.

Authors:  H Goldblatt; J Lynch; R F Hanzal; W W Summerville
Journal:  J Exp Med       Date:  1934-02-28       Impact factor: 14.307

View more
  2 in total

Review 1.  Drug therapy of renovascular hypertension.

Authors:  Talma Rosenthal
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 2.  ACE inhibitors in elderly patients with hypertension. Special considerations.

Authors:  M Ravid; D Ravid
Journal:  Drugs Aging       Date:  1996-01       Impact factor: 3.923

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.